Breast cancer tissue of celecoxib-treated patients showed a significantly increased expression of MHC class II genes, including HLA-DRα and HLA-DRβ2, CD74 (MHC class II invariant chain) and HLA-DM, but not HLA-DQ and HLA-DOA [see Additional file 4, Table S4]. This evidence concerns the gene HLA-DOA and breast carcinoma.